Anthony W. Opipari
Interim Chief Medical Officer and Executive Vice President, Translational Medicine · 1 filing · Latest: May 7, 2026
Odyssey Therapeutics, Inc.
| Ticker | Owner | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
ODTX | Anthony W. Opipari | Interim Chief Medical Officer and Executive Vice President, Translational Medicine | May 11, 2026 | Tax Withholding | $18.00 | 4 | $72 | 7,502 | |
ODTX | Anthony W. Opipari | Interim Chief Medical Officer and Executive Vice President, Translational Medicine | May 11, 2026 | Option Exercise | — | 541 | — | 7,506 | |
ODTX | Anthony W. Opipari | Interim Chief Medical Officer and Executive Vice President, Translational Medicine | May 11, 2026 | Conversion | — | 6,965 | — | 6,965 |